Welcome to our dedicated page for Codiak Biosciences news (Ticker: CDAK), a resource for investors and traders seeking the latest updates and insights on Codiak Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Codiak Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Codiak Biosciences's position in the market.
Tessera Therapeutics has secured over $300 million in Series C financing to advance its GENE WRITING technology aimed at curing genetic diseases. Investors include the Abu Dhabi Investment Authority and Alaska Permanent Fund Corporation. CEO Geoffrey von Maltzahn emphasizes the transformative potential of genetic medicine. The GENE WRITING platform enables precise modifications to DNA, unlocking new treatment possibilities for various conditions. Tessera's innovative approach positions it to potentially lead a new category in genetic medicine.
Codiak BioSciences (Nasdaq: CDAK) has presented new preclinical data on its engineered exosome candidate exoASO-C/EBPβ at the AACR Annual Meeting 2022. This candidate demonstrated significant anti-tumor activity by repolarizing myeloid cells in tumor and blood. Results showed a greater than 5-fold improvement in tumors and 11-12-fold in circulating blood compared to non-exosomal ASOs. Monotherapy with exoASO-C/EBPβ achieved up to 70% complete responses, enhancing response rates to 90% when combined with anti-PD1 therapy. The therapy targets C/EBPβ, crucial for immunosuppression in cancers.
Codiak BioSciences reported significant financial growth in its Q4 and full year 2021 results. Total revenues surged to $7.7 million for Q4 and $22.9 million for the year, primarily due to collaborations with Jazz and Sarepta. The company achieved a net income of $16.7 million for Q4, a turnaround from a net loss in 2020. R&D expenses rose to $17.4 million in Q4, reflecting ongoing development, while general and administrative costs increased to $6.9 million. Codiak anticipates further clinical data releases and IND application progress in 2022, positioning itself for future growth.
Codiak BioSciences (NASDAQ: CDAK) announced a significant breakthrough in cancer therapy with its engineered exosome, exoASO-STAT6, capable of reprogramming tumor-associated macrophages (TAMs). A recent study published in Science Advances demonstrates its impressive monotherapy anti-tumor activity in models of colorectal and hepatocellular carcinomas. Codiak plans to initiate a Phase 1 clinical trial in H1 2022, focusing on liver cancer, marking this as their first systemically administered candidate targeting a transcription factor. This innovative approach could redefine cancer treatments.
Cellarity has announced key appointments to its executive team, enhancing its expertise in drug development. Laurens Kruidenier, Ph.D., joins as Chief Scientific Officer to lead drug platform evolution, while Anna O’Driscoll becomes Chief People Officer to drive talent development. Parul Doshi is appointed Senior VP, Head of Data and Software Engineering to bolster data infrastructure. These changes underscore Cellarity's commitment to advancing its drug creation process, particularly its unique approach that examines cellular changes underlying diseases, applicable across multiple therapeutic areas.
Sporos Bioventures has announced the formation of a Strategic Advisory Board (SAB), chaired by Douglas E. Williams, Ph.D. The inaugural members include leading experts in precision oncology and immunology: Keith T. Flaherty, M.D., Bing Yao, Ph.D., and Douglas Hanahan, Ph.D. The SAB will support Sporos in advancing its research portfolio targeting unmet medical needs in cancer and immune diseases. This initiative reflects the company's commitment to innovation and collaboration in drug development.
Codiak BioSciences, a clinical-stage biopharmaceutical company, announced participation in the H.C. Wainwright Virtual BioConnect 2022 Conference from January 10 to January 13, 2022. CEO Douglas E. Williams, Ph.D., and CFO Linda C. Bain will be featured in a fireside chat with research analyst Mike King. The webcast will be available on demand starting January 10 at 7:00 a.m. EST on their website, with an archived replay accessible for 30 days.
Codiak is pioneering exosome-based therapeutics, aiming to address significant unmet medical needs across various disease areas.
Codiak BioSciences (Nasdaq: CDAK) announced promising preclinical data on its exoVACC™ exosome-based vaccine platform at the World Vaccine & Immunotherapy Congress 2021. The data demonstrate the candidate's potential to elicit robust immunity against various SARS-CoV-2 variants through strong antibody and T cell responses. Notably, the exosome construct showed a 100-fold higher antibody response compared to traditional recombinant proteins. The findings underscore the innovative design of Codiak's vaccine, which could lead to a comprehensive approach to combat COVID-19 and its variants.
Codiak BioSciences (Nasdaq: CDAK) announced that President and CEO Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, from 12:10-12:30 p.m. ET. The event will focus on Codiak's pioneering work in exosome-based therapeutics, aimed at treating diseases with high unmet medical needs. A webcast can be accessed via the Codiak website, with archived replays available for 30 days.
Codiak BioSciences (CDAK) has received FDA clearance for its Investigational New Drug Application (IND) for exoASO-STAT6, its first engineered exosome therapeutic for systemic administration. This candidate targets tumor-associated macrophages and demonstrated anti-tumor activity in preclinical models of hepatocellular carcinoma. The Phase 1 trial will assess safety and preliminary anti-tumor effects. Promising results from studies showed significant tumor growth reduction and complete remission in 50% of treated mice, with enhanced results when combined with anti-PD1 antibodies.
